Renal Cell Carcinoma (Kidney Cancer) Clinical Trials

12 recruitingLast updated: June 17, 2026

There are 12 actively recruiting renal cell carcinoma (kidney cancer) clinical trials across 10 countries. Studies span Not Applicable, Phase 1, Phase 3, Phase 4. Top locations include Nashville, Tennessee, United States, Lyon, France, Boston, Massachusetts, United States. Updated daily from ClinicalTrials.gov.


Renal Cell Carcinoma (Kidney Cancer) Trials at a Glance

12 actively recruiting trials for renal cell carcinoma (kidney cancer) are listed on ClinicalTrialsFinder across 6 cities in 10 countries. The largest study group is Not Applicable with 2 trials, with the heaviest enrollment activity in Nashville, Lyon, and Boston. Lead sponsors running renal cell carcinoma (kidney cancer) studies include Brigitta Rasmussen Villumsen, Centre Francois Baclesse, and A2 Biotherapeutics Inc..

Browse renal cell carcinoma (kidney cancer) trials by phase

Treatments under study

About Renal Cell Carcinoma (Kidney Cancer) Clinical Trials

Looking for clinical trials for Renal Cell Carcinoma (Kidney Cancer)? There are currently 12 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Renal Cell Carcinoma (Kidney Cancer) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Renal Cell Carcinoma (Kidney Cancer) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 112 of 12 trials

Recruiting
Phase 4

Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal Carcinoma

Metastatic Renal Cell CarcinomaLocally AdvancedRenal Cell Carcinoma (Kidney Cancer)
Centre Francois Baclesse83 enrolled16 locationsNCT07028125
Recruiting
Phase 1

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

Non-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)Colorectal Cancer (CRC)+4 more
Kura Oncology, Inc.300 enrolled38 locationsNCT06026410
Recruiting

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

Colorectal, CancerPancreatic CancerHead and Neck Squamous Cell Carcinoma (HNSCC)+14 more
A2 Biotherapeutics Inc.200 enrolled16 locationsNCT04981119
Recruiting
Not Applicable

Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy

Non-small Cell Lung CancerMelanoma (Skin Cancer)Invasive Mammary Carcinoma+5 more
Jessica Mezzanotte Sharpe25 enrolled1 locationNCT07555210
Recruiting

Validation of RCC Predicting Model With Emulated-target Trial

Prognostic Cancer ModelRenal Cell Carcinoma (RCC)Prognosis+4 more
Peking University Third Hospital4,700 enrolled1 locationNCT07117227
Recruiting

Patient-partnered Research in Investigating Fear of Cancer Recurrence in Kidney Cancer

Renal Cell Carcinoma (Kidney Cancer)Fear of Cancer Recurrence
Brigitta Rasmussen Villumsen105 enrolled3 locationsNCT07234656
Recruiting
Phase 3

Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC

Renal Cell Carcinoma (RCC)Clear Cell Renal Cell Cancer (ccRCC)Renal Cell Carcinoma (Kidney Cancer)+3 more
Telix Pharmaceuticals (Innovations) Pty Limited40 enrolled5 locationsNCT07197580
Recruiting

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

transitional cell carcinomaHepatocellular CarcinomaNon-small Cell Lung Cancer+1 more
Daniel Keizman300 enrolled1 locationNCT07485114
Recruiting
Phase 3

Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)

Renal Cell Carcinoma MetastaticRenal Cell Carcinoma (Kidney Cancer)Kidney Cancer Metastatic
Sun Yat-sen University252 enrolled9 locationsNCT06726421
Recruiting
Not Applicable

Targeted Abdominal CT in Conjunction With Lung Cancer Screening

Renal Cell Carcinoma (Kidney Cancer)Kidney CancersAAA - Abdominal Aortic Aneurysm+1 more
University of Cambridge6,272 enrolled1 locationNCT07171190
Recruiting

Application of Radiomics-based AI Models in Predicting Clinical Outcome of Patients With Renal Cell Carcinoma After Surgical Treatment

Renal Cell Carcinoma (Kidney Cancer)
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology400 enrolled1 locationNCT07118813
Recruiting
Phase 1

Study of 111In-XYIMSR-01 SPECT/CT in Patients With Metastatic Clear Cell Renal Cell

Renal Cell Carcinoma (Kidney Cancer)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins6 enrolled1 locationNCT07062549